Free Trial

Aura Biosciences Q1 2024 Earnings Report

Aura Biosciences logo
$8.41 +0.18 (+2.19%)
(As of 05:41 PM ET)

Aura Biosciences EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Aura Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aura Biosciences Announcement Details

Quarter
Q1 2024
Time
N/A
Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Aura Biosciences Earnings Headlines

Xoma (XOMA) Receives a Hold from TD Cowen
Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.”
In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation.
See More Aura Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email.

About Aura Biosciences

Aura Biosciences (NASDAQ:AURA), a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

View Aura Biosciences Profile

More Earnings Resources from MarketBeat